Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...

Many men with aggressive prostate cancer can experience a high rate of recurrence despite treatment. A new Phase 2 clinical trial at UC Davis Comprehensive Cancer Center unveiled clues as to why these ...

The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...

New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to ...

Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver ...

Early-stage trials of a new drug for advanced prostate cancer have yielded "remarkable" results, according to medical experts. This innovative treatment, an immunotherapy designed to harness the ...

Despite announcing the prostate cancer drug will advance, Oric’s stock dropped nearly 19%.

MRI reports and biopsy pathology reports were extracted from a cohort of 1,360,866 patients with PCa in the VA Cancer Registry System or the VA Corporate Data Warehouse, with 155,570 patients having ...

Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver ...